N Engl J Med 2009;361: Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., D.Phil., Salim Yusuf, F.R.C.P.C., D.Phil., John Eikelboom, M.D., Jonas Oldgren, M.D., Ph.D., Amit Parekh, M.D., Janice Pogue, M.Sc., Paul A. Reilly, Ph.D., Ellison Themeles, B.A., Jeanne Varrone, M.D., Susan Wang, Ph.D., Marco Alings, M.D., Ph.D., Denis Xavier, M.D., Jun Zhu, M.D., Rafael Diaz, M.D., Basil S. Lewis, M.D., Harald Darius, M.D., Hans-Christoph Diener, M.D., Ph.D., Campbell D. Joyner, M.D., Lars Wallentin, M.D., Ph.D., and the RE-LY Steering Committee and Investigators* Dabigatran versus Warfarin in Patients with Atrial Fibrillation R2 박소영 / Prof 김진배

Atrial fibrillation increases the risk of stroke and death. Vitamin K antagonists, such as warfarin, reduced the risk of stroke and death but increase the risk of hemorrhage as compared with control therapy Multiple interactions with food & drugs Frequent laboratory monitoring A need for new anticoagulant agent INTRODUCTION

DABIGATRAN A potent, direct, competitive inhibitor of thrombin An absolute bioavailability of 6.5% 80% renal excretion Serum half-life hours Not require regular monitoring

METHODS - PATIENTS Atrial fibrillation documented on ECG Previous stroke or TIA LVEF <40 % NYHA class Ⅱ or higher HF symptoms within 6 months Age >75 years or 65~74 years + DM, HTN, or CAD Exclusion criteria Severe heart-valve disorder Stroke within 14 days or severe stroke within 6 months Increased the risk of hemorrhage A Creatinine clearance <30 mL/min Active liver disease Pregnancy

METHODS - PROCEDURE Dabigatran was administered, in a blinded fashion, in capsules containing either 110 mg or 150 mg of the drug, to be taken twice daily Warfarin was administered, in an unblinded fashion, in tablets of 1, 3, or 5 mg and was adjusted locally to an INR of 2.0 to 3.0, with the INR measured at least monthly. Follow-up visits occurred 14 days after randomization, at 1 and 3 months, every 3 months thereafter in the first year, and then every 4 months until the study ended.

METHODS - OUTCOMES Primary outcome Stroke or systemic embolism Primary safety outcome Major hemorrhage Secondary outcomes Stroke, systemic embolism, death Other outcomes MI, pulmonary embolism, TIA, hospitalization Primary net clinical benefit outcome Stroke, systemic embolism, pulmonary embolism, myocardial infarction, death, major hemorrhage

RESULTS

v

CONCLUSION In patients with atrial fibrillation, Dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.